The conversation discusses reliable brands for RU58841, with recommendations for RUdirect and Receptorchem. Users also mention Anageninc as a known option for RU58841 in Europe and the UK.
Ell-Cranell and Eucapil are discussed as hair loss treatments, with Ell-Cranell being a weak estrogen and DHT inhibitor that may reduce hair loss without systemic side effects. Alfatradiol is the active ingredient in these products.
People discuss obtaining oral Minoxidil in Germany, with suggestions including splitting larger tablets, using a pipette with topical Minoxidil, and purchasing from pharmacies in Andorra or France. Some users share their experiences with pill cutters and alternative methods for accurate dosing.
Fluridil is available in Germany, but oral minoxidil and dutasteride are hard to obtain. Users discuss using treatments like Eucapil, RU58841, oral minoxidil, and clascoterone for hair loss, with concerns about side effects and effectiveness.
The conversation discusses obtaining an online EU prescription for Bimatoprost/Lumigan for hair loss without an in-person doctor visit. The user is seeking alternatives to physical consultations for this treatment.
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
ET-02, a new hair loss treatment, shows promising results with a 6-fold increase in hair count, potentially outperforming minoxidil by activating stem cells in hair follicles. Further trials are ongoing to confirm its efficacy and safety, with potential market release in the future.
The conversation is about finding reputable clinics in Belgium, the Netherlands, France, or Germany for PRP with double centrifugation or exosome therapy for hair loss. The user seeks recommendations based on personal experiences or good reviews.
Finasteride and dutasteride are still available in the EU, with a warning about potential suicidal thoughts. The benefits of these treatments are deemed greater than the risks.
The conversation discusses using topical finasteride as an alternative to oral medication for hair loss, with mentions of minoxidil, microneedling, ketoconazole shampoo, and other treatments. A user shares their experience with topical finasteride and other treatments, noting improved hair density.
ET-02 (RS 5441) shows promising results for hair growth, performing better in humans than in mice. There is debate over the effectiveness compared to minoxidil, with some users wanting more detailed data.
The conversation is about finding a reliable source for oral minoxidil and finasteride in the EU after a previous supplier stopped offering them. Suggestions include Pharmacy Tristaina in Andorra and bgpharma, with users sharing their experiences and dosages.
Kopexil (Aminexil) is not approved as a drug in the US and Europe because it is marketed as a cosmetic, which requires less testing and regulation. L'Oreal's 1.5% Aminexil is noted to reduce hair shedding, but its efficacy as a drug is not proven.
Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.
Dutasteride is safer than finasteride for long-term use, with fewer sexual side effects. Users experience better hair regrowth and fewer side effects with dutasteride.
A 26-year-old male uses 0.5mg Dutasteride every other day and 5mg Minoxidil daily for hair loss, showing significant improvement in three months. He reports no side effects.
A user is considering trying Aevin hair creme, which contains ingredients like jojoba oil and saw palmetto, despite skepticism about its effectiveness compared to treatments like finasteride, minoxidil, or hair transplants. They are wary of the product's legitimacy due to the lack of reviews outside the brand's website.
A user shared their experience of easily obtaining dutasteride in Italy using an online prescription service, noting the lower cost compared to their home country. They plan to bring back a large supply due to the ease of purchase and lack of strict prescription checks.
Amplifica is developing new molecules for hair growth, with clinical trials expected soon, while Engraft Technologies is improving FUE robotic technology to make hair transplants faster and cheaper. Users express interest in the timeline for AMP-303 and concerns about high costs and effectiveness of current treatments.
The discussion is about using ASCEplus HRLB exosomes for hair loss treatment, which combines 10 billion exosomes with growth factors, nutrients, biotin, and copper tripeptide. The treatment is expensive and typically administered via scalp injections, but in Europe, it's done with microneedling.
The conversation discusses Melatonin's potential benefits for AGA and a product called "Asatex" by ASATONA AG. The company was uncooperative when contacted for purchase inquiries.
User asks where to purchase exosomes/AAPE for microneedling hair loss treatment. Links to research on hair regeneration therapy, stem cell therapy, exosome therapy, and dermal exosomes provided.
Finasteride and Dutasteride do not cause depression or "Post Finasteride Syndrome," with concerns often linked to the nocebo effect and preexisting mental health issues. The EU is unlikely to ban these drugs, but access may become more restricted due to ongoing debates.
Eucapil/fluridil is discussed as a potential treatment for hair loss, with questions about its effectiveness and why it isn't a primary treatment. Minoxidil, finasteride, and RU58841 are also mentioned as treatments.
Balancing estradiol (e2) levels may alleviate post-finasteride syndrome (PFS) symptoms. Hormone tests, including testosterone and e2, are recommended for those experiencing PFS.
The user stopped using finasteride due to side effects and is considering Fluridil (Eucapil) as an alternative for hair loss treatment. They are exploring other options like RU58841 and are interested in the experiences of others with Fluridil, noting its good safety profile despite the cost.